High-Dose vs. Standard-Dose Influenza Vaccine in Heart Failure: A Prespecified Analysis of the DANFLU-2 Trial
Skaarup KG. et al, (2025), Circulation: Heart Failure
Risk of Myocarditis or Pericarditis with High-Dose versus Standard-Dose Influenza Vaccine: A Prespecified Analysis of the Randomized DANFLU-2 Trial
LANDRAY M. et al, (2025), JAMA Network Open
Recommended methodologies for clinical investigations of high-risk medical devices – Conclusions from the European Union CORE–MD Project
LANDRAY M. et al, (2025), The Lancet Regional Health. Europe
High-dose versus standard-dose inactivated influenza vaccine and cardiovascular risk: the DANFLU-2 trial
LANDRAY M. et al, (2025), European Heart Journal
Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial
Zhou J. et al, (2025), EClinicalMedicine
Sotrovimab versus usual care in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY)
HORBY P. et al, (2025), The Lancet Infectious Diseases
Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2025), Lancet Infect Dis
Clinical Implications of Slope of GFR in Clinical Trials of CKD Progression
Greene T. et al, (2025), Clinical Journal of the American Society of Nephrology, 20, 632 - 641
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.
Mayne KJ. et al, (2025), Nephrol Dial Transplant, 40, 720 - 730
Correction: Large simple randomized controlled trials-from drugs to medical devices: lessons from recent experience.
Buccheri S. et al, (2025), Trials, 26
Large simple randomized controlled trials-from drugs to medical devices: lessons from recent experience.
Buccheri S. et al, (2025), Trials, 26
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.
Judge PK. et al, (2024), Nephrol Dial Transplant
ALDOSTERONE SYNTHASE INHIBITION WITH VICADROSTAT (BI 690517) TO REDUCE RISKS OF KIDNEY AND CARDIOVASCULAR DISEASE IN CHRONIC KIDNEY DISEASE: A RATIONALE FOR THE EASi-KIDNEY TRIAL
Judge P. et al, (2024), Nephrology Dialysis Transplantation
Accelerating Evidence Generation: Addressing Critical Challenges and Charting a Path Forward
LANDRAY M., (2024), Journal of Clinical and Translational Science
Overcoming the barriers to better evidence generation from clinical trials
LANDRAY M., (2024), Trials